NOVARTIS

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Clinical Trials

Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women

Phase 1

Completed

Conditions: Postmenopausal Osteoporosis

First Posted Date: 2006-11-02

Last Posted Date: 2007-05-28

Lead Sponsor: Novartis

Target Recruit Count: 56

Registration Number: NCT00395395

Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome

Phase 3

Completed

Conditions: Hypertension
Metabolic Syndrome

First Posted Date: 2006-11-01

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis

Target Recruit Count: 45

Registration Number: NCT00394745

Locations: 🇨🇭
Novartis, Basel, Switzerland

VALIDATE Valsartan and Supportive Measures - Impact on Drug Adherence of Treated Hypertensive Patients

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2006-11-01

Last Posted Date: 2017-05-18

Lead Sponsor: Novartis

Target Recruit Count: 206

Registration Number: NCT00394823

Locations: 🇨🇭
Novartis, Basel, Switzerland

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Phase 2

Completed

Conditions: Irritable Bowel Syndrome With Diarrhea (IBS-D)

Interventions: Drug: Placebo
Drug: DNK333

First Posted Date: 2006-10-31

Last Posted Date: 2017-02-27

Lead Sponsor: Novartis

Target Recruit Count: 180

Registration Number: NCT00394173

Locations: 🇨🇦
Investigative Site, Quebec, Canada

Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol
Drug: Formoterol
Drug: Placebo to formoterol
Drug: Placebo to indacaterol

First Posted Date: 2006-10-27

Last Posted Date: 2011-08-18

Lead Sponsor: Novartis

Target Recruit Count: 1732

Registration Number: NCT00393458

Locations: 🇬🇧
Novartis Investigator Site, Swansea, United Kingdom
🇪🇸
Novartis Investigative Site, Madrid, Spain
🇹🇷
Novartis, Istanbul, Turkey

Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Tobramycin solution for inhalation 300 mg

First Posted Date: 2006-10-25

Last Posted Date: 2011-08-29

Lead Sponsor: Novartis

Target Recruit Count: 123

Registration Number: NCT00391976

Maintaining Bone Strength in Men With Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

First Posted Date: 2006-10-25

Last Posted Date: 2009-11-23

Lead Sponsor: Novartis

Target Recruit Count: 300

Registration Number: NCT00391950

A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2006-10-25

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 224

Registration Number: NCT00392262

Locations: 🇨🇭
Novartis, Basel, Switzerland

Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Levodopa/carbidopa
Drug: Levodopa/carbidopa/entacapone

First Posted Date: 2006-10-25

Last Posted Date: 2011-03-15

Lead Sponsor: Novartis

Target Recruit Count: 95

Registration Number: NCT00391898

Locations: 🇪🇸
Fundación Hospital de Alcorcón, Alcorcón (Madrid, Spain
🇪🇸
Centro Médico Teknon, Barcelona, Spain
🇪🇸
Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain

and more 23 locations

Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer

First Posted Date: 2006-10-24

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 99

Registration Number: NCT00391690

Locations: 🇩🇪
Novartis Investigative Site, Tuebingen, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy